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 Letter to the Editor 
Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in 
Chronic Myeloid Leukaemia (CML) cells 
To the Editor,  
The current treatment for chronic myeloid leukaemia (CML) is tyrosine kinase inhibitors (TKI), which 
inhibit BCR-ABL1 phosphorylation activity. Despite success of TKI therapy in causing complete 
cytogenetic response (i.e., 0% Philadelphia (Ph) chromosome-positive cells detected by cytogenetics in 
the bone marrow), in the majority of chronic phase (CP) CML patients, nearly all patients have minimal 
residual disease detectable by sensitive Q-PCR owing to the inability of TKI agents to eliminate 
persistent, primitive, leukemic stem cells (LSC) [1,2]. We believe E2F1 is a critical transcription factor 
(TF) for CML LSC survival. E2F1 binds to retinoblastoma protein in a cell-cycle dependent manner so is 
responsible for regulating cell proliferation and apoptosis. In CML, BCR-ABL1 signaling leads to an up-
regulation of E2F1.The process starts with BCR-ABL1 driven up-regulation of hsa-mir183 in Ph+ cells 
which then down-regulates its direct target, EGR1 subsequently upregulating E2F1 (personal 
communication). Although our studies suggest that inhibition of E2F1 itself may be promising 
therapeutically, transcription factors are notoriously challenging as drug targets. 
Small synthetic oligomers composed of aromatic amino acids, called polyamides (PA) are able to bind 
to predetermined DNA sequences in the minor groove of DNA. PA molecules are resistant to cellular 
proteases and can target genomic DNA of cancer cells in vitro and in vivo. PA molecules inhibit gene 
expression through either competitive-binding to TF binding sites or inhibition of RNA polymerase [3-6]. 
The PA used in this study was designed to recognize the general sequence WGWGGW (where W = A 
or T). To inhibit E2F1 transcriptional activity, we explored targeting a PA binding site GTGGA within 100 
base pairs (bp) of the 5' end of the consensus E2F1 binding site (TTTCGC) in the promoter region of 
the TF’s target genes. To determine the ability of our PA to disrupt E2F1 activity, we asked: how would 
our PA affect CP CML cell cycle, proliferation and apoptosis; how would it alter cell function, e.g. colony 
formation capacity, of CP CML CD34+ cells; and how would it change E2F1 target gene expression 
alone or in combination with TKIs? 
Primary CD34+ cells from CP CML patients stored in the University of Glasgow’s Paul O’Gorman 
Leukemia Research Centre hematological cell research bank with informed consent (West of Scotland 
Research Ethics Committee (REC) reference 15-WS-0077) were chosen samples for this study. CP 
CML CD34+ cells were seeded at 2x105/mL in physiological growth factor supplemented serum free 
medium [7]; PA was tested at three different concentrations (0.3, 3 or 10 μM); nilotinib was used at 2 
μM.  
Viability was determined by flow cytometry by staining cells with Annexin V / DAPI. Our data were 
suggestive of our PA (Fig. 1A) having some effect on restricting cell viability with respect to untreated 
control after 72h in culture (Fig. 1B). However, this effect was not as great as with nilotinib on its own. 
Interestingly, the combination of PA (3 μM) and nilotinib (2 μM) showed a trend towards a co-operative 
negative effect on number of surviving CP CML cells. Indeed this was mirrored in the colony forming 
assay (Fig. 1C). As our hypothesis is predicated on BCR-ABL1 TK activity driving E2F1 expression, this 
was an unexpected result worthy of further investigation.  We propose residual E2F1 function may 
explain the apparently increased effect with the combination; and suggests pulsed dosing of one agent 
before the other might be more beneficial.  
CP CML CD34+ cells were also stained with carboxyfluorescein succinimidyl ester (CFSE), and further 
identified by anti-human anti-CD34 surface staining, to assess the ability of these cells to divide (Fig. 
1D) as a reduced number of viable cells could come about through the processes of increased cell 
death and/or control of cell cycle and division. PA had no effect on CP CML CD34+ cell potential to 
divide in the time frame tested (72h) (Fig. 1D & E) hence reduced numbers of viable cells must be 
through impairment of survival.  
 
 
                                                                                                                                                                                                                                                                                                                                              
 
        
    
Figure 1. Analysis of CP CML CD34
+
 cell viability and proliferation 72 h after being treated with PA, nilotinib or the 
combination.      A. Schematic representation of the PA used to inhibit DNA-binding of E2F1 in the target binding site.  B. 
Comparative analysis of PA and nilotinib on CP CML CD34
+
 cell viability in vitro. C. The number of colony forming cells (CFC) 
per 3,000 live cells plated after 12 days culture in semi-solid medium was scored (grey bars, left hand axis).  To determine the 
absolute number of CFC, a correction factor was applied allowing for the drug effect, so multiplying to find the number of CFC 
produced had all remaining cells in the dish been plated (right hand axis) and normalizing to the no drug control (NDC). D. 
Tracking of cell division with CFSE staining of CD34
+
 cells surviving 72h drug treatment in liquid culture suggested no effect of 
PA on the ability of the cells to proliferate with respect to the untreated control. Front to back, 0.3M (thick dotted line), 3M, 
(thin dotted line), 10 M (unbroken line), CFSE
max
 (cells arrested with Colcemid
®
, filled curve; peak with mean fluorescence 
intensity in the FITC channel of approximately 10
4
) E. Calculating the absolute number of cells per division as the product of 
the percentage gated times viable cell count confirmed the lack of effect of PA alone on the ability of CP CML CD34
+
 cells to 
divide (according to the method of Prost et al., Nature 2015; doi:10.1038/nature15248). 
We next investigated the modulation of gene expression by our PA in these cells. From a list of 4,300 
possible target genes, 42 were identified with PA binding sequence (5'-GTGGA-3') within 100 bp and 5’ 
to the E2F1 consensus binding sequence. Levels of expression of these genes were then investigated 
among normal and CP CML CD34+ hematopoietic stem/progenitor cells (HSC/HPC) within a publically 
available dataset on the Stemformatics portal [8] (Fig. 2). Primers were designed for 17 of the 42 most 
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(x 10^5)  % 
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max
 12 0.216 10.8 0.194 12.5 0.225 13.6 0.245 
Div 1 13.8 0.248 12.7 0.229 12.8 0.230 13.8 0.248 
Div 2 21.7 0.347 23.5 0.376 23.6 0.378 22.7 0.363 
Div 3 31.9 0.574 34.2 0.616 32.4 0.583 32.5 0.585 
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differentially expressed genes in CP CML CD34+ cells. Nine of those 17 primer pairs (MRRF, MCM2, 
SF3B4, GNA13, PSMB8, PET112L, TRIM45, ZNF354B, RARS2) presented efficiencies ranging 
between 88 and 110% (Table 1) and were used to investigate gene expression changes by qPCR 
induced by our PA (Fig. 3). After 24h, RARS2 and TRIM45 genes showed down-regulation with all PA 
three concentrations (0.3, 3 and 10 μM) (Fig. 3). RARS2 is involved in mitochondrial protein translation 
while TRIM45 has an established role in proliferation, development, oncogenesis, and apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Heat-map showing expression values of genes having a PA binding sequence 5’ to E2F1 transcription factor 
consensus binding sequence. Gene expression values for 42 candidate genes within Gerber et al., publically available 
dataset accessible via the Stemformatics website, of normal and CML hematopoietic stem (HSC) and hematopoietic 
progenitor cells (HPC). Darker blue shows lower, while darker red shows higher expression levels with respect to 
housekeeping genes.  Screenshots captured from LEUKomics portal of Stemformatics [8]. 
Gene name DNA concentration (ng/mL) Slope Efficiency (%) 
MRRF 3.125 - 100 -3.547 91 
MCM2 3.125 - 100 -3.109 110 
SF3B 3.125 - 100 -3.515 93 
GNA13 3.125 - 100 -3.530 92 
PSMB8 3.125 - 100 -3.257 103 
PET112L 3.125 - 100 -3.654 88 
TRIM45 6.25 - 100 -3.618 89 
ZNF354B 6.25 - 50 -3.535 92 
RARS2 3.125 - 100 -3.479 94 
 
Table 1: Primer efficiencies. In the primer efficiency test for genes of interest based on their qPCR standard curve (by 
SYBR
®
 green detection based on Qiagen RT
2
 Profiler PCR Arrays kit) the resultant slope of the line was used in the equation 
[-1+10
(-1/slope)
] x 100 whereby the primer efficiency as a percentage for each primer pair can be determined. The nine genes 
from among 17 that had acceptable efficiencies between approximately 90 and 110% and were taken forward are shown. 
 
 Figure 3. RT-qPCR gene expression results for CP CML CD34
+
 cells after 24h in vitro treatment with PA. TRIM45 and 
RARS2 showed down-regulation with all PA three concentrations (0.3, 3 and 10 μM). Ct values were normalized to GAPDH and RNF20 
housekeeping genes. Relative gene expression levels were calculated by the standard 2
-ΔΔCt
 method. 
In summary, we showed a minor-groove binding PA inhibits the transcriptional activity of E2F1, which in 
turn caused a reduction in CP CML cell viability and function in combination with TKI. Studies are 
currently underway to systematically survey DNA sequences up/downstream from the E2F1 consensus 
sequence using a PA compound library and establish an ‘interactome’ map of E2F1 function in CML 
cells. A deeper understanding of this TF could ultimately translate into the development of TF inhibitors 
as a novel anti-cancer drug target. 
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